Analysis of the new anti-tumor drug Da Youtong: blocking blood vessels to feed the tumor "starvation"

Source: China News Net

Pharmaceutical News June 22, the anti-tumor drug Dayoutong was approved by the China National Drug Administration (NMPA). The indications are advanced non-squamous non-small cell lung cancer and metastatic colorectal cancer.

Reporter learned this news from Cinda Biopharmaceutical Group, an independent drug researcher and developer, on the 19th. Cinda Bio said that this is their second monoclonal antibody drug after Dabshu® (Sintilimab Injection).

Analysis of the principle mechanism: blocking blood vessels to "starve the tumor"

According to introduction, lung cancer is the first malignant tumor with high morbidity and mortality in China, while the incidence and mortality of colorectal cancer ranks third and fifth respectively.

"Popularly speaking, this drug can block vascular feeding and eventually "starve" the tumor in the body." The head of the Cinda biological research and development team said that the principle mechanism of the anti-tumor of Dayuton® is by blocking vascular endothelial growth factor VEGF inhibits tumor angiogenesis, cuts off blood supply to the tumor area, inhibits tumor growth and metastasis, induces tumor cell apoptosis, and thus achieves anti-tumor therapeutic effects.

The person in charge also said that Dayotone® can be combined with platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic, or relapsed non-squamous cell non-small cell lung cancer, or with fluoride Pyrimidine-based chemotherapy is used to treat patients with metastatic colorectal cancer.

Drug development hot spots: immunotherapy and anti-angiogenesis therapy

Dr. Hui Zhou, Vice President of Oncology Biomedical Science and Strategic Oncology Department, introduced that the combination of immunotherapy and anti-angiogenesis therapy has a synergistic effect on the mechanism of action, which is currently the hot spot for clinical development of anti-tumor drugs.

Zhou Hui revealed that the results of their ongoing Phase Ib preliminary clinical trial of Dayoutong® and Daboshu® in the treatment of advanced hepatocellular carcinoma will be announced at the ASCO annual meeting this year. "The data shows that the combined use of these two drugs has achieved initial positive results in patients with advanced hepatocellular carcinoma," he said.

He also said that Dayoutong® is an anti-VEGF monoclonal antibody with international quality, and has authorized its commercial rights in the United States and Canada to the US pharmaceutical company Coherus, which means Cinda’s ability in the field of macromolecular drug research and development Obtain international recognition.

Make patients affordable: two drugs are included in the national medical insurance catalog

High-quality biopharmaceuticals, in the final analysis, must be affordable to the common people. And this is also the "initial heart" since the establishment of Cinda.

In November 2019, Dabex® became the only PD-1 inhibitor to enter the new version of the National Medical Insurance Catalog. The annual treatment cost for patients is less than 100,000 yuan, which is only one-twelfth of that of similar drugs in the United States. The reporter learned that Dayoutong will also be included in the national medical insurance catalog, so that the common people can buy and afford it.

Que Hong, senior vice president of Cinda Biology, emphasized that it took 8 years from the establishment of the project to the listing of the company, "a scientifically rigorous target has been established through a lot of research." She said that the industrial base for the production of the drug is also in line with NMPA in China , US FDA, European EMA GMP standards. Clinical data shows that the drug has a good therapeutic effect on advanced non-small cell lung cancer and metastatic colorectal cancer.